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The mechanism by which interlcukin-lor (IL-lo) activates NF-~13 DNA-binding activity is not completely understood. While it is well established 
Lhat protein kinase C can activate NF-~13, neither protein kinase C nor protein kinase A appears to be critical in the induction of NF-h-B by IL-la. 
Since a number of growth factors signal via protein tyrosine kinusc, in this study WC examined apossible involvement of protein tyrosine kinase 
in the IL-la-induced NF--KB. The results howed that in the murine pre-B cell ine 7Oi?/3 and in the murine T cell line EL-4 6.1 ClO.iL-1 a-induced 
NF-xB was associated with transient increase in protein tyrosine kinasc activity. Pre-treatment of these cell lines with herbimycin A, an inhibitor 
of tyrosine kinase activity. blocked the IL-la-enhanced protein tyrosine kinasc activity and the IL-la-induced NF-KB DNA-binding activity. 
Herbimycin A at concentrations sufficient to block IL-la-induced NF-KB did not block the phorbol l2-myristate 13-ncetare(PMA)-induced NF-KB. 
The data suggest that IL-la and PMA activate NF-XB by different pathways and that induction of NF-KB DNA-binding activity by IL-1 might 
be dependent on protein tyrosine phosphotylation. 
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1, INTRODUCTION 
The pre-B lymphocyte cell line ?OZ/3 and the T- 
lymphoma cell line EL-4 6.1 Cl0 have proven to be 
useful systems to study the biological effects of IL-l. In 
702/3, IL-la induces expression of the K immunoglo- 
bulin light chain gene while in EL-4 6.1 Cl0 IL-la 
stimulates expression of IL-2 [l-3]. Expression of the K 
light chain and IL-2 genes cirn be regulated by the ubi- 
quitous transcription factor NF-XB [2-4]. In most rest- 
icg cells, NF-h-B is located in the cytoplasm in an inac- 
tive state complexed with an inhibitor, IrcB. Treatment 
of cells with phorbol 12.myristate 13-acetate (PMA) 
causes the dissociation of this complex, allowing NF-KB 
to translocate to the nucleus where it binds to its 
cognate DNA element [5,6]. Based on this observation 
it was postulated that protein kinase C can activate 
NF-KB DNA-binding activity in vivo. This postulate 
was further supported by the observation that phospho- 
rylation in vitro of IlcB by protein kinase C blocks its 
ability to inhibit NF-KB DNA-binding activity [7]. Al- 
though there is strong evidence that phorbol ester acti- 
vates NF-KB via a protein kinase C-dependent 
pathway, the mechanisms mediating activation of NF- 
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KB by physiological inducers have not been defined 
[1,7-91. For example, while IL-l and tumor necrosis 
factor (TNF) activate protein kinase C [S-lo], the in- 
duction of NF-xl3 by these physiological agents is in- 
dependent of protein kinase C [8,9]. The role of CAMP 
in the lymphokine-induced NF-rcB has also been exam- 
ined. Shirakawn et al. reported that IL-l increases in- 
tracellular levels of CAMP and concluded that protein 
kinase A is a key step in the pathway leading to activa- 
tion of NF-KB [1 13. However, in contrast o this study, 
two laboratories have now shown that IL-la-stimulated 
CAMP is not sufficient to fully activate NF-rcB [1,12]. 
Thus, mechanisms other than those involving protein 
kinase A or protein kinase C must trigger IL-l -induced 
activation of NF-KB. 
A number of important physiological agents signal 
through protein tyrosine kinases [13]. It is, therefore, 
possible that IL-l-induced NF-KB DNA-binding activ- 
ity might involve activation of protein tyrosine kinase. 
To test this hypothesis, we have measured protein ty- 
rosine kinase activity following treatment of cells with 
IL-la and examined the IL-l&induced NF-KB in the 
presence of a protein tyrosine kinase inhibitor, herbi- 
mycin A [14-17). In vitro, herbimycin A inhibits the 
tyrosine kinasc activity of V-SK [16]. In vivo, herbimycin 
A reduces phosphorylation of proteins on tyrosine 
residues [173. The effect of herbimycin A appears to be 
specific since it reverses ce!! transformation induced by 
tyrosine kinase oncogenes but has no effect on trans- 
formation induced by other kinase oncogenes [15,16], 
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2. MATERIALS AND METHODS 
The 70213 cell line was derived from a nitrosourea induced tumor 
as described previously [ 181. Our 70213 cells came from Drs. Kincadc 
and Paige [ 181. EL-4 6. I Cl0 is a variant subclone derived from EL-4 
thymoma nd came IO us from Drs. Lowcnthal and MacDonald [3], 
Cells were grown in complete RPMI 1640 medium supplcmentcd with 
5% FCS, 2 mM glutamine, 50 ,uM mercaptoethanol, penicillin (100 
units/ml), and streptomycin (0.01%) at 37OC and humidifled with a 
7%:93% CO&ir gas mixture. 
2.2. Reugcnrs 
Recombinant human IL-la was a gift from Dr, SK. Dower (Im- 
mune% Corp., Seattle, WA). Herbimycin A was isolated as described 
previously [IS]. RPM1 1640 mediaand Protein Tyrosine Kinasc Assay 
Kit was purchased from Gibco-BRL (Gaithcrsburg, MD). 
IO’cells were wushcd once with I ml PBS and once with I ml oflysis 
buffer (IO mM HEPES. IO mM KCI. and I.5 mM MgCI:, pH 7.9. 
4°C). Cells were lysed by suspending the cell pellet in 20 pl of lysis 
buffer containina 0.1% NP-40 for IO min on ice. The soluble fraction 
ofccll lysates wa~scparatcd from theparticulatefraction by microcen- 
trifugation (5 min at 12,000 x g, 4°C). The supcrnatant representing 
the soluble fraction of the cell lysaies was saved (-70°C). The pellet 
consisted mostly of intact nuclei. Nuclear proteins were exxucted as 
described previously by Dignam [I91 and were saved (-70°C) for 
electrophorctic mobility shift assay (EMSA). 
2.4. Profehr ryrositw kirrux curiviry ~tr~asurww~fs 
Tyrosine kinasc activity in the soluble fraction of the cell lysate was 
assayed using the RR-SRC assay system as per manufacturers pro- 
tocol (Protein Tyrosine Kinase Assay System, GibcomBRL, Gai- 
thersburg, MD). Briefly, aliquots containing equal amount of protein 
were incubated with or without substrate peptide in the presence of 
[$zP]ATP (30°C). Protein was TCA-precipitated and incubated with 
a phosphoccllulosc disc. After extensive wash ‘:P counts were 
measured using a scintillation counter. Counts representing RR-SRC 
phosphorylation werecalculated asthcdifference betweencounts with 
or without RR-SRC peptide. 
2.5. ~/~~rro,&or&c tnobilty shiJr rissay (EMSA) 
The NP+cB probe was a synthetic double-stranded oligonucleotidc 
with the sequence STGACAGAGGOGACTTTCCGAGAGGA3’. 
The oligonuclcotide probe was end-lsbclled using [y-‘zP]ATP and T4 
polynucleotidc kinuse. The binding reaction of the DNA probe with 
nuclear protein extracts and polyacrylamide gel electrophoresis were 
performed as described previously [I], 
3. RESULTS AND DISCUSSION 
To test a hypothesis that IL-la activates NF-~93 
DNA-binding activity by activating protein tyrosine 
kinase, we Arst examined whether IL-la stimulates pro- 
tein tyrosine kinase activity. 7OZ/3 or EL-4 6.1 C 10 cells 
were treated with IL-la and at given time points 10’ cell 
aliquots were harvested and protein tyrosine kinase ac- 
tivity in the soluble fraction of the cell lysates was as- 
sayed using the RR-SRC peptide substrate (RR- 
LIEDAEYAARG). This peptide is derived from the 
amino acid sequence surrounding the phosphorylation 
site in pp60”” and is specific for protein tyrosine kinasc 
[20]. Fig. 1 illustrates results from these experiments. In
both cell lines IL-la induced a transient increase in 
protein tyrosine activity; first detected at 2 min, it 
Fig. I. Time course of protein tyrosinc kinase activity in cell lysatn 
from 702/3 and EL-4 6.1 Cl0 cells after IL~la trcaiment. Cells at lo6 
cells/ml in RPM1 1640/5% FCS were pre-treated with or without one 
hour of herbimycin A (20 j@ml) pulse. After a wash, cells were 
resuspended in fresh RPM1 1640/S% FCS media and were treated with 
IL-la; 702/3 with 1O‘1o M and EL-4 6.1 Cl0 with 1O-‘z M. At given 
time points protein tyrosine kinasc activity in the soluble fractions of 
the cell lysates was assayed as per the manufacturers protocol (Protein 
Tyrosine Kinase Assay System, GibcoaBRL). Results are represented 
as means +- SE of at least fourdifferent experiments done in duplicates. 
peaked at 5 min and was down at 15 min. Activation 
of cells through a number of known receptors involves 
activation of protein tyrosine kinases 121-231. Some re- 
ceptors, like the insulin, PDGF or EGF receptors are 
tyrosine kinases, while others like the IL-2 receptor or 
the surface immunoglobulin increase tyrosine phospho- 
rylation even though they are not tyrosine kinases 
[24,25]. EL-4 6.1 Cl0 express type I IL-l receptor that 
is structurally different from the type II IL-1 receptor 
expressed on 7OZ/3 cells [26,27]. Neither type I nor type 
II IL-1 receptor is a tyrosine kinase [26,27], but as in the 
case of the IL-2 receptor ut the surface immunoglobulin 
our study shows that IL-1 receptors can nonetheless 
stimulate protein tyrosine kinase activity. It remains to 
be determined whether or not the same protein tyrosine 
kinase(s) are activated by IL-la in 7CW3 and EL4 6.1 
Cl0 cells. As in the case of the lymphoid cell lines used 
in this study, activation of protein tyrosine kinase activ- 
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Fig* 2. Time course of NF-rcB DNA-binding activity after IL-I u treat- 
ment of 702’3 and EL-4 6.1 Cl0 cells. Cells were treated as described 
in Fig. I. At the given time points nuclear proteins were extracted from 
ID x IO” cells. NF-KB DNA-binding activity in nuclear extracls was 
assayed by clectrophoretic mobility shift assay (EMSA) using the KB 
double-stnnded synthetic oligonuclcotide [I], 
ity by IL-1 has also been recently reported in fibroblasts 
[28]. 
In 70213 and EL-4 6.1 Cl0 cells IL-la activates NF- 
KB DNA-binding activity [8]. Next we wished to deter- 
mine the kinetics of IL- 1 a-induced NF-h-l3 and compare 
it to the time course of IL-la-induced protein tyrosinc 
kinase activity. After treatment with lL-la, cells were 
harvested, nuclei isolated and levels of NF-KB in nu- 
clear extracts were assayed by EMSA using a synthetic 
oligonucleotide containing the KB enhancer element 
(GGGGACTTTCC) from the K light chain immunoglo- 
bulin gene [2]. Results from these experiments are 
shown in Fig. 2. As was the case with induction of 
protein tyrosine kinase activity, IL-la induced transient 
activation of NF-KB DNA-binding activity. DNA- 
binding activity of NF-KB was first detected 5 min fol- 
lowing stimulation with IL-la, peaked at 30 min and 
was nearly down to baseline at 4 h. Comparison of Figs. 
1 and 2 shows that IL-la-enhanced protein tyrosine 
kinase activity appears to precede the activation of NF- 
KB. 
To test whether protein tyrosine kinase might be in- 
volved in the IL-l-induced NF-KB DNA-binding activ- 
ity we used the irreversible protein tyrosine kinase in- 
hibitor herbimycin A [14-171. Since herbimycin A is an 
irreversible inhibitor of protein tyrosine kinases we 
reasoned that pre-treating cells with a pulse of this drug 
will allow us to use higher concentration of this drug 
while maintaining ood cell viability. Accordingly, cells 
were pre-treated with various concentrations of herbi- 
ll?yeifi A a1’16 a&r one hour of treatment ceiis were 
washed, resuspended in fresh media and were then 
treated with IL-la. After 30 min treatment (time at 
which IL-la induces maximal NF-KB response (Fig, 2)), 
A 
B 
C 
EL-4 
IL=la 
122468 
Fig. 3, EMSA of NF-h-B after IL-la or PMA treatment in cells prc- 
treated will1 various concentrations ofhcrbimycin A pulse. Ceils were 
pre-treated with (lanes 2-5) or without (lanes 1 and 6) one hour of 
hetbirnycin A pulse with the indicated concentrations. After a wash 
cells were resuspended in fresh RPM1 1640/s% FCS media and were 
treated for 30 min (lanes 2-6) with either lo-” M IL-lo (70213 cells; 
panel A), lo-’ M PMA (70213 cells; panel B) or with IO-” M IL-la 
(EL-4 (5.1 ClO; panel C). NFvvB was assayed by EMSA as in Fig. 2. 
cells were harvested and nuclear extracts were assayed 
for NF-KB activity by EMSA. Results from these ex- 
periments are shown in Fig. 3. Pre-treatment of 7OZ/3 
cells with 2 ,ug/ml herbimycin A significantly reduced 
the ability of IL-la to activate NF-XB and at 20 &ml 
the [L-la-induced NF-KB was completely blocked (Fig. 
3A). The effect of herbimycin A on IL-la-induced NF- 
KB in EL-4 6.1 Cl0 cells was similar (Fig. 3C). 
Previous results from this and other laboratories have 
shown that the mechanism of activation of NF-KB by 
PMA may be different from the mechanisms used by 
physiological inducers uch as IL-1 or TNF [8,9]. There- 
fore, we next tested the effects of herbimycin A on 
PMA-induced activation of NF-XB in 7OZ/3 cells. We 
have previously shown that PMA is an effective acti- 
vator of NF-rcB and protein kinase C in 70213 cells 
[8,10]. As before, cells were pre-treated with or without 
a one hour herbimycin A pulse and after a wash cells 
were incubated with lo-’ M PMA. After 30 min of 
treatment with PMA, nuclear extracts were assayed for 
NF-KB using the KB probe and EMSA. Gels from this 
experiment are shown in Fig. 3B. These results showed 
that in a sharp contrast o the ii-l& rrsulis, herbimycin 
A did not block the PMA-induced activation of NF-KB. 
The effects of PMA and IL- I a in herbimycin A-treated 
EL-4 6.1 C 10 cells could not be compared because PMA 
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does not activate NF-KB in these cells [S]. Similarly to 
these results, a differential effect of herbimycin A has 
previously been reported for the T-cell receptor- and 
PMA-mediated IL-2 production and IL-2 receptor ex- 
pression in human peripheral T cells [29]. 
To show that herbimycin A blocks stimulation of 
tyrosine kinase(s) we assayed protein tyrosine kinase 
activity in cell lysates derived from IL-l& and herbi- 
mycin A-treated cells. As illustrated in Fig. 1, pre-treat- 
ment of 702/3 and EL-4 61 Cl0 cells with a 20 &ml 
herbimycin A pulse blocked the IL-la-enhanced protein 
tyrosine kinase activity. 
Our studies demonstrate differential effects of herbi- 
mycin A on the induction of NF-KB in response to 
IL-la and PMA. These observations indicate that the 
two inducing agents activate NF-h-B DNA-binding ac- 
tivity by different pathways. While in the case of PMA 
there is a strong evidence for a protein kinase C-depend- 
ent pathway [7-93, the IL-2 pathway appears to be in- 
dependent of the known isoforms of protein kinase C 
[8]. This is in agreement with studies from other labo- 
ratories which showed that TNF [9] and the phasphat- 
ase inhibitor, okadaic acid [30], activate NF-KB DNA- 
binding activity independent of protein kinase C. 
Although all the cellular effects of herbimycin A are not 
yet known, this and a number of other studies suggest 
that the inhibitory effect is specific for protein tyrosine 
kinases [ 14, IS]. Thus, the results from the present study 
point to a protein tyrosine kinase-dependent event 
transducing the IL-la-induced NF-xl3 DNA-binding 
activity. 
Although it now appears that IL-la and PMA ac- 
tivate NF-KB by different pathways, it remains to be 
established whether or not these pathways overlap and 
at which point they may converge. It is conceivable that 
the two pathways converge at an early step in the cas- 
cade of events leading to the activation of NF-KB. In 
fact, it cannot be ruled out that the shared portion of 
such a pathway, if it exists, may include a protein tyro- 
sine kinase and/or yet unidentified isoform of protein 
kinase C. On the other hand, it may turn out that the 
IL-la and the PMA pathways do not overlap until they 
both terminate by phosphorylating different sites of 
IKB. A gene encoding IKB-like activity has recently been 
cloned [31]. The predicted protein sequence contains a 
consensus equence for tyrosine and protein kinase C 
phosphorylation sites. It is possible that IKB could dis- 
sociate from NF-KB by phosphorylation of either one 
of the IKB phosphorylation sites. This would be consis- 
tent with the hypothesis that PMA activates NF-KB 
DNA-binding activity by stimulating protein kinase C 
which phosphorylates IKB on the serine residue, while 
IL-ltx activates NF-KB by stimulation of protein tyro- 
sine kinase which phOSphOiy!rtteS I,:?? 0:: the tyrosine 
residue. Phosphoamino acid analysis of in vivo 3’P-la- 
belled IKB following PMA and IL-la treatments will be 
required to test this hypothesis. 
It appears that the phosphorylation-induced dissocia- 
tion of IicB from NF-KB and the resulting activation of 
DNA-binding [5-71 might be only one of many com- 
ponents of a complicated network of events and factors 
regulating ene expression from the KB enhancer ele- 
ment. For example, a number of constitutive and in- 
ducible KB-binding proteins have recently been de- 
scribed, Most but not all appear to be homologous to 
re/ [32,33]. Furthermore, we have recently identified a 
constitutive 65 kDa KB-binding phosphoprotein that is 
closely associated with an inducible serine/threonine 
kinase(s) [34]. It remains to be defined how the 65 kDa 
rcB-binding phosphoprotein and its associated kinase 
activity is structurally and functionally related to the 
other constitutive and inducible xB-binding complexes. 
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